BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25922552)

  • 1. Serum and urine biomarkers for human renal cell carcinoma.
    Pastore AL; Palleschi G; Silvestri L; Moschese D; Ricci S; Petrozza V; Carbone A; Di Carlo A
    Dis Markers; 2015; 2015():251403. PubMed ID: 25922552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose.
    Cinque A; Vago R; Trevisani F
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
    Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
    Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting responsive phenotypes through cytokine and angiogenic factor analysis.
    Rini B
    Ann Oncol; 2012 Jan; 23(1):6-7. PubMed ID: 22100695
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunoreactive low-molecular-weight epidermal growth factor in urine of patients with renal cell carcinoma.
    le Coutre P; Bock S; Jakse G; Petrides PE
    Urol Res; 1992; 20(4):293-6. PubMed ID: 1509636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine metabolomics for kidney cancer detection and biomarker discovery.
    Ganti S; Weiss RH
    Urol Oncol; 2011; 29(5):551-7. PubMed ID: 21930086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Ding M; Zhou W; Chen W; Mo W; Guo X; Li Y; Ji C; Liu G; Diao W; Guo H
    Clin Transl Med; 2024 Feb; 14(2):e1575. PubMed ID: 38356436
    [No Abstract]   [Full Text] [Related]  

  • 8. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative membrane proteomics: a technical advancement in the search of renal cell carcinoma biomarkers.
    Raimondo F; Corbetta S; Savoia A; Chinello C; Cazzaniga M; Rocco F; Bosari S; Grasso M; Bovo G; Magni F; Pitto M
    Mol Biosyst; 2015 Jun; 11(6):1708-16. PubMed ID: 25926002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of renal cell carcinoma.
    Sankineni S; Brown A; Cieciera M; Choyke PL; Turkbey B
    Urol Oncol; 2016 Mar; 34(3):147-55. PubMed ID: 26094171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of platelet count with clinicopathological significance and prognosis in renal cell carcinoma: a systematic review and meta-analysis.
    Gu L; Li H; Gao Y; Ma X; Chen L; Li X; Zhang Y; Fan Y; Zhang X
    PLoS One; 2015; 10(5):e0125538. PubMed ID: 25955026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals.
    Song W; Yeh CR; He D; Wang Y; Xie H; Pang ST; Chang LS; Li L; Yeh S
    Oncotarget; 2015 Aug; 6(22):19290-304. PubMed ID: 26079540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron.
    Büttner F; Winter S; Rausch S; Reustle A; Kruck S; Junker K; Stenzl A; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E
    Eur Urol; 2015 Dec; 68(6):1016-20. PubMed ID: 26072688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
    Courthod G; Tucci M; Di Maio M; Scagliotti GV
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.
    Xiao H; Zeng J; Li H; Chen K; Yu G; Hu J; Tang K; Zhou H; Huang Q; Li A; Li Y; Ye Z; Wang J; Xu H
    Oncotarget; 2015 May; 6(15):13201-15. PubMed ID: 26036633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of CHIP leads to increased angiogenesis via VEGF-VEGFR2 pathway and poor prognosis in human renal cell carcinoma.
    Sun C; Li HL; Chen HR; Shi ML; Liu QH; Pan ZQ; Bai J; Zheng JN
    Sci Rep; 2015 May; 5():9774. PubMed ID: 26021863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma.
    Kim JY; Lee SH; Moon KC; Kwak C; Kim HH; Keam B; Kim TM; Heo DS
    J Urol; 2015 Oct; 194(4):1112-9. PubMed ID: 25997916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-27a promotes cell proliferation and metastasis in renal cell carcinoma.
    Peng H; Wang X; Zhang P; Sun T; Ren X; Xia Z
    Int J Clin Exp Pathol; 2015; 8(2):2259-66. PubMed ID: 25973137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.
    Chang Y; Xu L; An H; Fu Q; Chen L; Lin Z; Xu J
    Int J Clin Exp Pathol; 2015; 8(2):1594-603. PubMed ID: 25973044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
    Peng J; Mo R; Ma J; Fan J
    World J Surg Oncol; 2015 May; 13():175. PubMed ID: 25951903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.